Advertisement

Ads Placeholder
Loading...

BPH Global Ltd

BP8.AXASX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.002
$0.00(0.00%)
Australian Market opens in 61h 24m

BPH Global Ltd Fundamental Analysis

BPH Global Ltd (BP8.AX) shows moderate financial fundamentals with a PE ratio of -0.94, profit margin of -4.22%, and ROE of 95.35%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE95.35%
Cash Position10.90%
PEG Ratio0.01

Areas of Concern

Operating Margin-4.13%
Current Ratio0.27
We analyze BP8.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -343.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-343.8/100

We analyze BP8.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

BP8.AX struggles to generate sufficient returns from assets.

ROA > 10%
-2.75%

Valuation Score

Excellent

BP8.AX trades at attractive valuation levels.

PE < 25
-0.94
PEG Ratio < 2
0.01

Growth Score

Weak

BP8.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

BP8.AX shows balanced financial health with some risks.

Debt/Equity < 1
0.00
Current Ratio > 1
0.27

Profitability Score

Weak

BP8.AX struggles to sustain strong margins.

ROE > 15%
95.35%
Net Margin ≥ 15%
-4.22%
Positive Free Cash Flow
No

Key Financial Metrics

Is BP8.AX Expensive or Cheap?

P/E Ratio

BP8.AX trades at -0.94 times earnings. This suggests potential undervaluation.

-0.94

PEG Ratio

When adjusting for growth, BP8.AX's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values BPH Global Ltd at -0.97 times its book value. This may indicate undervaluation.

-0.97

EV/EBITDA

Enterprise value stands at -2.66 times EBITDA. This is generally considered low.

-2.66

How Well Does BP8.AX Make Money?

Net Profit Margin

For every $100 in sales, BPH Global Ltd keeps $-4.22 as profit after all expenses.

-4.22%

Operating Margin

Core operations generate -4.13 in profit for every $100 in revenue, before interest and taxes.

-4.13%

ROE

Management delivers $95.35 in profit for every $100 of shareholder equity.

95.35%

ROA

BPH Global Ltd generates $-2.75 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.75%

Following the Money - Real Cash Generation

Operating Cash Flow

BPH Global Ltd generates limited operating cash flow of $-2.46M, signaling weaker underlying cash strength.

$-2.46M

Free Cash Flow

BPH Global Ltd generates weak or negative free cash flow of $-2.47M, restricting financial flexibility.

$-2.47M

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

BP8.AX converts -25.15% of its market value into free cash.

-25.15%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.94

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.008

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.97

vs 25 benchmark

P/S Ratio

Price to sales ratio

10.52

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.27

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.95

vs 25 benchmark

ROA

Return on assets percentage

-2.75

vs 25 benchmark

ROCE

Return on capital employed

0.99

vs 25 benchmark

How BP8.AX Stacks Against Its Sector Peers

MetricBP8.AX ValueSector AveragePerformance
P/E Ratio-0.9428.54 Better (Cheaper)
ROE95.35%738.00% Weak
Net Margin-421.87%-43982.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio0.272806.01 Weak Liquidity
ROA-274.78%-14624.00% (disorted) Weak

BP8.AX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BPH Global Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ